For patients who have spent hours in an infusion chair, the transition to subcutaneous cancer treatment—a simpler injection under the skin—can feel like a small but meaningful relief. Yet determining when to switch from intravenous (IV) infusions to subcutaneous (sub-q) delivery is not always simple. The decision depends on factors such as diagnosis, treatment stage, insurance coverage, and personal comfort, all of which must be carefully considered with a care team.
Not every cancer drug has a subcutaneous version. The first consideration is confirming whether the medication being taken is approved for sub-q delivery. Even if it is, FDA approval does not guarantee it is suitable for every patient. Some formulations are limited to specific cancer types or treatment combinations, and individual health factors may make it unsuitable. The good news is that research confirms sub-q versions are just as effective as IV infusions.
“Every single patient has asked me if [the sub-q version] is just as effective,” said Roxana Dronca, MD, a hematologist-oncologist at Mayo Clinic. “They are really reassured to hear that it is.”
For some patients, the switch occurs when treatment no longer requires an IV line or port. If chemotherapy or other IV medications are no longer needed, sub-q injections can replace them, offering convenience without compromising effectiveness. Kelly Morrow McCarthy, diagnosed with stage 3C metaplastic HER2-positive breast cancer in 2024, made the transition after her port was removed. Her final treatment included trastuzumab and pertuzumab, which were available as a combined sub-q injection (Phesgo).
“Switching over to a medication that is just an injection felt better for me, psychologically,” McCarthy said. “When I got my port removed, it felt like taking a step away from being a cancer patient and a step toward survivorship.” She also appreciated how quickly the sub-q treatment could be given. “The speed of getting the injection was a major pro,” McCarthy said. “The part where I was sitting in the chair and getting medication took about 10 minutes.”
Allergic reactions prompt urgent switch
For others, the decision arises from a different experience. Willis Brown’s treatment plan changed abruptly after an allergic reaction to his IV infusion nearly triggered anaphylactic shock. His doctor recommended switching to a sub-q version, and Brown recalled the decision as straightforward: “You’re the doctor. Let’s do it.” While sub-q options reduce infusion-related reactions, ongoing monitoring remains important—reactions, though rarer, can still occur.
Related Post: Cancer Recurrence Depends on Tumor Type and Spread
Nima Palma’s shift came after nearly a decade of multiple myeloma treatment. By then, the hours spent in infusion chairs had become exhausting. When her doctor offered a sub-q alternative for her ongoing medication, the choice was clear. “The sub-q injection only took about 10 minutes, plus prep and bloodwork,” Palma said. “I was there maybe an hour total. Compared to the two-and-a-half hours for an IV infusion, it’s much quicker. I’m happy it became available when I was receiving it.”
The emotional impact of treatment, whether fear of needles, the physical burden of ports, or the mental strain of long clinic visits, plays a role in these decisions. For some, sub-q delivery is not just about convenience but about regaining a sense of normalcy. “I think [subcutaneous versions] are more patient-friendly and can address many of these needs,” Dr. Dronca said.
Insurance hurdles delay patient-preferred treatments
However, insurance coverage often complicates the process. Even if a sub-q option is medically suitable, some plans may not cover it, particularly if the IV version is equally effective and costs less. Erin Cobain, MD, a medical oncologist and co-director of the breast cancer clinical research team at the University of Michigan Health Rogel Cancer Center, noted that patient preference usually drives the conversation, but insurance dictates the outcome. “Overwhelmingly, our patients generally prefer the subcutaneous versions, because it shortens their time in the infusion chair, potentially allows them to get through therapy without needing a port placement,” she said. “But sometimes insurance doesn’t cover it.”
When coverage is denied, financial navigators or oncology social workers can help explore appeals or patient assistance programs. The goal is to access the treatment while aligning it with what feels right for the patient, whether that means speed, comfort, or simply a break from the infusion chair.
Therapy stage dictates IV vs. sub-q
The decision to switch depends on how a patient’s therapy evolves. For some, the shift only becomes possible after their treatment plan no longer requires IV medications. Jorge J. Nieva, MD, a medical oncologist and lung cancer specialist at the USC Norris Full Cancer Center, explained that if a patient still relies on IV chemotherapy or other infusion-based therapies, maintaining the IV route for all medications may be more practical. “If you’re already starting an IV to receive chemotherapy, you might as well receive the IV form,” he said. This approach avoids the need for separate needle insertions or additional clinic visits.